AZN

AstraZeneca PLC (AZN) Stock Analysis: Solid Growth with a 12% Revenue Boost, But Is It a Buy?

AstraZeneca PLC (NASDAQ: AZN), a titan in the healthcare sector, continues to capture investor attention with its robust pipeline and strategic partnerships aimed at advancing pharmaceutical innovation. With a market..

AstraZeneca wins US approval for Imfinzi in early gastric and GEJ cancers

AstraZeneca has received US approval for Imfinzi combined with FLOT chemotherapy for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers...

AstraZeneca PLC (AZN) Stock Analysis: A Healthcare Giant with Promising Growth and Strategic Collaborations

AstraZeneca PLC (NASDAQ: AZN), a leading player in the global healthcare sector, continues to capture the attention of investors with its robust market presence and strategic collaborations. Headquartered in Cambridge,..

AstraZeneca Plc to invest $2 billion in major Maryland manufacturing expansion

AstraZeneca has confirmed a $2 billion investment to expand its manufacturing presence in Maryland, including a larger biologics facility in Frederick and a new clinical manufacturing site in Gaithersburg...

AstraZeneca PLC (AZN): Investor Outlook on a $276 Billion Healthcare Giant with Promising 4.55% Upside

AstraZeneca PLC (NYSE: AZN) stands as a towering presence in the healthcare sector, boasting a robust market capitalization of $276.26 billion. Specializing in the development and commercialization of prescription medicines,..

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 10.35% Upside Potential in the Healthcare Giant

AstraZeneca PLC (AZN) stands as a prominent player in the healthcare sector, particularly within the general drug manufacturing industry. This biopharmaceutical powerhouse, headquartered in Cambridge, UK, is making significant strides..

AstraZeneca PLC (AZN) Stock Analysis: Exploring the 13% Upside Potential Amid Strong Buy Ratings

AstraZeneca PLC, trading under the stock symbol AZN, stands as a formidable player in the healthcare sector, specifically within the drug manufacturers’ industry. With its headquarters in Cambridge, United Kingdom,..

Astrazeneca PLC (AZN) Stock Analysis: Riding the 11.75% Potential Upside Wave

AstraZeneca PLC (AZN), a towering presence in the biopharmaceutical sector, continues to capture investor attention with its promising growth trajectory and robust pipeline of prescription medicines. With a market capitalization..

AstraZeneca PLC (AZN) Stock Analysis: Navigating Growth with a 6% Upside Potential

AstraZeneca PLC (AZN), a titan in the healthcare sector, continues to make significant strides in the pharmaceutical industry. Headquartered in Cambridge, UK, AstraZeneca is a key player in the discovery,..

AstraZeneca Tezspire approved in the US for chronic rhinosinusitis with nasal polyps

The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and over with inadequately controlled chronic rhinosinusitis with nasal polyps...

AstraZeneca PLC (AZN) Stock Analysis: 6.2% Potential Upside Fuels Investor Interest

AstraZeneca PLC (AZN), a stalwart in the healthcare sector, continues to capture investor attention with its robust market position and promising growth potential. Headquartered in Cambridge, United Kingdom, AstraZeneca is..

AstraZeneca Plc reaches agreement with Trump administration to cut US drug prices

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients...

Astrazeneca PLC (AZN)

⚠️ No article content returned.

..

AstraZeneca PLC (AZN) Stock Analysis: A Strong Buy with an 18.45% Upside Potential

AstraZeneca PLC (NASDAQ: AZN), a heavyweight in the healthcare sector, continues to capture investor attention with its robust market position and promising growth prospects. As a leading biopharmaceutical company based..

AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings and an 18.45% Potential Upside

AstraZeneca PLC (NASDAQ: AZN), a titan in the healthcare sector, specifically within the drug manufacturers industry, boasts a commanding presence with a market capitalization of $228.69 billion. Headquartered in Cambridge,..

AstraZeneca PLC (AZN): Investor Outlook with a 14.54% Potential Upside and Strong Buy Ratings

AstraZeneca PLC (AZN) stands prominently as a global leader in the healthcare sector, with a particular focus on the discovery, development, and commercialization of prescription medicines. With a market capitalization..

AstraZeneca’s Tezspire recommended for EU approval in chronic rhinosinusitis with nasal polyps

The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic rhinosinusitis with nasal polyps...

AstraZeneca PLC (AZN) Stock Analysis: Exploring Growth Potential and Analyst Ratings

AstraZeneca PLC (AZN), a titan in the healthcare sector, continues to capture investor attention with its expansive portfolio in the drug manufacturing industry. With a market capitalization of $253.94 billion,..

AstraZeneca PLC (AZN) Stock Analysis: Exploring an 8.40% Upside Potential

AstraZeneca PLC (AZN), a titan in the healthcare sector, continues to capture investor attention with its robust portfolio and strategic collaborations. Known for its innovation in drug manufacturing, AstraZeneca is..

AstraZeneca PLC (AZN) Stock Analysis: Riding the 6.96% Upside Potential with Strong Buy Ratings

AstraZeneca PLC (NASDAQ: AZN), a powerhouse in the healthcare sector and a leading player in the drug manufacturing industry, stands out with its impressive market capitalization of $251.5 billion. Headquartered..

Search

Funds

AZN

AstraZeneca wins US approval for Imfinzi in early gastric and GEJ cancers

AstraZeneca has received US approval for Imfinzi combined with FLOT chemotherapy for adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers...

AstraZeneca Plc to invest $2 billion in major Maryland manufacturing expansion

AstraZeneca has confirmed a $2 billion investment to expand its manufacturing presence in Maryland, including a larger biologics facility in Frederick and a new clinical manufacturing site in Gaithersburg...

AstraZeneca Tezspire approved in the US for chronic rhinosinusitis with nasal polyps

The US FDA has approved AstraZeneca and Amgen’s Tezspire (tezepelumab) as an add-on maintenance treatment for patients aged 12 and over with inadequately controlled chronic rhinosinusitis with nasal polyps...

AstraZeneca Plc reaches agreement with Trump administration to cut US drug prices

AstraZeneca has signed a landmark agreement with President Donald J. Trump’s administration to reduce the cost of prescription medicines for American patients...

AstraZeneca’s Tezspire recommended for EU approval in chronic rhinosinusitis with nasal polyps

The European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Tezspire (tezepelumab) for adult patients with chronic rhinosinusitis with nasal polyps...
Search

Funds

AZN

FTSE 100

Funds